← Back to Search

CTLA-4 Inhibitor

Vopratelimab for Cancer

Phase 1 & 2

Waitlist Available

Research Sponsored by Jounce Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 48 months

Awards & highlights

Study Summary

This trial is for people with cancer who have participated in a previous study of the drug vopratelimab. The trial will provide continued access to the drug for these people.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 48 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~48 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

% subjects with adverse events (AEs)

% subjects with clinically significant change from baseline in clinical laboratory tests

% subjects with serious adverse events (SAEs)

Secondary outcome measures

Median progression free survival (PFS)

Trial Design

3Treatment groups

Experimental Treatment

Group I: Vopratelimab with nivolumabExperimental Treatment2 Interventions

Participants will continue to receive vopratelimab in combination with nivolumab per parent protocol.

Group II: Vopratelimab with ipilimumabExperimental Treatment2 Interventions

Participants will continue to receive vopratelimab in combination with ipilimumab per parent protocol.

Group III: VopratelimabExperimental Treatment1 Intervention

Participants will continue to receive vopratelimab monotherapy per parent protocol.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ipilimumab

FDA approved

Nivolumab

FDA approved

Vopratelimab

Not yet FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Jounce Therapeutics, Inc.Lead Sponsor

5 Previous Clinical Trials

580 Total Patients Enrolled

Ellen Hooper, MDStudy DirectorJounce Therapeutics, Inc.

4 Previous Clinical Trials

481 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research endeavor still open for enrollment?

"Sadly, recruitment for this clinical trial has been completed. It was uploaded to the web on March 10th 2020 and the most recent update occurred September 9th 2022. However, those searching for other trials will find 482 studies with malignancies actively recruiting as well as 766 Vopratelimab related experiments taking part in participant enrolment."

Answered by AI

What other experiments have been performed with Vopratelimab?

"Vopratelimab was initially tested in 2009 at Texas Children's Hospital and has since seen 365 clinical trials come to fruition. Currently, 766 research studies are active with a notable number of them held in Houston, Texas."

Answered by AI

What symptoms is Vopratelimab designed to alleviate?

"Vopratelimab is typically used to address anti-angiogenic therapy, but it can also be employed as a treatment for malignant neoplasms, unresectable melanoma or squamous cell carcinoma."

Answered by AI

What is the scope of participants in this medical experiment?

"Unfortunately, the recruitment for this study has concluded. First posted on March 10th 2020 and last updated September 9th 2022, it is no longer actively seeking participants. On the other hand, there are presently 482 clinical trials searching for individuals with malignancies and 766 recruiting those taking Vopratelimab."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Vopratelimab (JTX-2011) Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

2020. "Vopratelimab (JTX-2011) Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04319224.